Physician profile
David A Smith
NPI 1821037599
$772.53
in general payments reported to CMS, 2019-2025
15 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.96 · 2021: $70.51 · 2022: $97.42 · 2023: $172 · 2024: $216 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169.59 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $96.19 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $89.08 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $77.82 | 2020-2022 | |
| Novo Nordisk INC | $65.56 | 2022-2025 | |
| Sanofi Pasteur INC. | $42.27 | 2022-2023 | |
| Abbott Laboratories | $37.31 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $35.17 | 2024-2025 | Verquvo, Vaxneuvance, Gardasil 9 |
| Seqirus USA INC | $33.66 | 2024-2025 | Flucelvax, Fluad |
| Vertex Pharmaceuticals Incorporated | $30.83 | 2025 | |
| Lilly USA, LLC | $21.17 | 2024 | Mounjaro |
| Inspire Medical Systems, INC. | $19.72 | 2025 | Inspire |
| Exact Sciences Corporation | $19.58 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $17.43 | 2024 | Aptima |
| Astrazeneca Pharmaceuticals Lp | $17.15 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.